MEndoB
Atopic Dermatitis
Pre-clinicalActive
Key Facts
About Micreos
Micreos is a private, pre-clinical stage biotech leveraging a proprietary engineered endolysin platform to develop targeted, resistance-resistant protein therapeutics. The company's lead candidate, MEndoB, is being developed for Atopic Dermatitis (AD), targeting the pathogenic S. aureus that aggravates the condition, with plans to enter clinical trials in late 2026. With a seasoned leadership team and a focused strategy on high-unmet-need dermatology, Micreos aims to establish a foundational therapy for AD and potentially expand into other indications driven by pathogenic triggers.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |
| AX-158 | Artax Biopharma | Phase 2 |